Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in two investor conferences in August and September 2026, providing a platform to discuss the company’s business and engage with the investment community. President and CEO Dr. Seth Lederman will speak at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, from 1:30 p.m. to 1:55 p.m. ET, and will also hold one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16.
The announcements come at a pivotal time for Tonix, which recently received approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. This flagship medicine represents a significant advancement in addressing a chronic condition that affects millions worldwide, offering new hope to patients who have had limited therapeutic options. The company’s participation in these conferences highlights its focus on communicating the potential of TONMYA to investors and the broader healthcare community.
Beyond TONMYA, Tonix is leveraging its CNS commercial infrastructure to support its migraine products, Zembrace SymTouch and Tosymra, which are already on the market. The company is also exploring the full therapeutic potential of TONMYA through Phase 2 clinical trials evaluating its efficacy in major depressive disorder and acute stress disorder, potentially expanding its indications and market reach. If successful, these trials could position TONMYA as a versatile treatment for multiple CNS conditions, significantly increasing its commercial value.
Tonix’s pipeline extends into rare diseases and immunology, with TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. Additionally, the company is advancing immunology programs, including TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs demonstrate Tonix’s commitment to addressing high unmet medical needs across diverse therapeutic areas.
The company’s involvement in these conferences is strategically important as it seeks to attract investment and partnerships to support its ongoing research and development. The presentations and meetings will allow investors to gain insights into Tonix’s strategic direction, clinical progress, and commercialization efforts. Tonix’s recent approval and its pipeline advancements position it as a notable player in the biotech sector, particularly in the CNS space.
Investors and industry observers will be watching closely as Tonix presents at these events, especially given the potential of TONMYA to capture significant market share in the fibromyalgia treatment landscape. The company’s ability to effectively communicate its value proposition will be crucial in maintaining investor confidence and securing the resources needed to advance its pipeline. For more information about Tonix Pharmaceuticals, visit the company’s newsroom at https://ibn.fm/TNXP.
